SCHEMBL1305348

SCHEMBL1305348

CN(C)CC(=O)Nc1cccc2c1C(=O)c1c(NC(=O)CN(C)C)cccc1C2=O

nearest known ligand 0.76

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TERT O14746 13/20 0.76
CCNE2 O96020 1/20 0.56
CDK4 P11802 1/20 0.56
CCND1 P24385 1/20 0.56
CCNE1 P24864 1/20 0.56
CDK2 P24941 1/20 0.56
MEN1 O00255 1/20 0.55
ALDH1A1 P00352 1/20 0.55
POLB P06746 1/20 0.55
GAA P10253 1/20 0.55
MAPT P10636 1/20 0.55
DNMT1 P26358 1/20 0.55
RAD52 P43351 1/20 0.55
SMARCA2 P51531 1/20 0.55
KMT2A Q03164 1/20 0.55
MAOA P21397 1/20 0.55
PARP14 Q460N5 1/20 0.51
PTPRC P08575 1/20 0.49
PTPN13 Q12923 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1304157 0.87 TERT (0.67) TERTCCNE2CDK4CCND1CCNE1
SCHEMBL8707846 0.87 TERT (1.00) TERTMEN1ALDH1A1POLBGAA
SCHEMBL1305202 0.85 TERT (0.76) TERTMEN1ALDH1A1POLBGAA
SCHEMBL12110611 0.85 TERT (0.67) TERTCCNE2CDK4CCND1CCNE1
SCHEMBL12110465 0.84 TERT (0.62) TERTCCNE2CDK4CCND1CCNE1
SCHEMBL1304218 0.83 TERT (0.68) TERTMEN1ALDH1A1POLBGAA
SCHEMBL8717734 0.82 TERT (1.00) TERTMEN1ALDH1A1POLBGAA
SCHEMBL12110694 0.80 TERT (0.81) TERTMEN1ALDH1A1POLBGAA
SCHEMBL1304035 0.80 TERT (0.64) TERTMEN1ALDH1A1POLBGAA
SCHEMBL1679959 0.80 TERT (0.64) TERTMEN1ALDH1A1POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8053583-B2 Anti-cancer compound and manufacturing method thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-11-08 US disclosed
US-8053583-B2 Anti-cancer compound and manufacturing method thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-11-08 US disclosed
US-8053583-B2 Anti-cancer compound and manufacturing method thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-11-08 US disclosed
US-20100145070-A1 ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2010-06-10 US disclosed
US-20100145070-A1 ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2010-06-10 US disclosed
US-20100145070-A1 ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF NATIONAL DEFENSE MEDICAL CENTER (TW) 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100145070-A1 ANTI-CANCER COMPOUND AND MANUFACTURING METHOD THEREOF DCK, DHPS, DHX15 TERT 3131/4885CCNE2 302/4885CDK4 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.